Charles River Laboratories International (CRL) Long-Term Investments (2019 - 2025)
Charles River Laboratories International has reported Long-Term Investments over the past 9 years, most recently at $207.0 million for Q4 2025.
- Quarterly results put Long-Term Investments at $207.0 million for Q4 2025, down 5.21% from a year ago — trailing twelve months through Dec 2025 was $207.0 million (down 5.21% YoY), and the annual figure for FY2025 was $207.0 million, down 5.21%.
- Long-Term Investments for Q4 2025 was $207.0 million at Charles River Laboratories International, up from $194.6 million in the prior quarter.
- Over the last five years, Long-Term Investments for CRL hit a ceiling of $218.4 million in Q4 2024 and a floor of $60.6 million in Q1 2022.
- Median Long-Term Investments over the past 5 years was $158.6 million (2022), compared with a mean of $158.1 million.
- Biggest five-year swings in Long-Term Investments: surged 189.5% in 2023 and later crashed 37.25% in 2024.
- Charles River Laboratories International's Long-Term Investments stood at $149.6 million in 2021, then grew by 22.02% to $182.6 million in 2022, then crashed by 32.83% to $122.7 million in 2023, then soared by 78.02% to $218.4 million in 2024, then fell by 5.21% to $207.0 million in 2025.
- The last three reported values for Long-Term Investments were $207.0 million (Q4 2025), $194.6 million (Q3 2025), and $216.1 million (Q2 2025) per Business Quant data.